We are very happy and proud to announce that the highly esteemed scientific journal Science Advances has published a research article describing how we discovered and developed two antibodies targeting TRPV1 (moduli-selective antagonist for pain) and KRAS (mutant-selective antagonist for cancer), respectively. These are two clinically highly important targets that were previously considered undruggable with antibodies. We did it with AbiProt, our in-house developed high-tech/proteomics technology that we believe has the potential to bring several novel antibody medicines to large patient populations in multiple disease areas.
Science Advances 16 Apr 2021: Vol. 7, no. 16, eabe6397 DOI: 10.1126/sciadv.abe6397
You can read our Press Release clicking here:
English Version: Science Advances publishes proteomics technology from Oblique Therapeutics AB with a potential to bring several novel antibody medicines to large patient populations in multiple disease areas
Swedish Version: Science Advances publicerar artikel om proteomikteknik från Oblique Therapeutics AB som kan bidra till utveckling av nya antikroppsläkemedel till stora patientpopulationer inom flera sjukdomsområden